HRP20161484T1 - Postupak za proizvodnju 5-bifenil-4-amino-2-metil-pentanske kiseline - Google Patents
Postupak za proizvodnju 5-bifenil-4-amino-2-metil-pentanske kiseline Download PDFInfo
- Publication number
- HRP20161484T1 HRP20161484T1 HRP20161484TT HRP20161484T HRP20161484T1 HR P20161484 T1 HRP20161484 T1 HR P20161484T1 HR P20161484T T HRP20161484T T HR P20161484TT HR P20161484 T HRP20161484 T HR P20161484T HR P20161484 T1 HRP20161484 T1 HR P20161484T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- image
- formula
- compound according
- hydrogen
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 25
- 150000001875 compounds Chemical class 0.000 claims 169
- 150000003839 salts Chemical class 0.000 claims 147
- 239000001257 hydrogen Substances 0.000 claims 96
- 229910052739 hydrogen Inorganic materials 0.000 claims 96
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 89
- 238000000034 method Methods 0.000 claims 72
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 61
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 35
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 238000006243 chemical reaction Methods 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 23
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 22
- 229920006395 saturated elastomer Polymers 0.000 claims 20
- -1 pyrrolidinylmethyl Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 238000005984 hydrogenation reaction Methods 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 10
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000002950 monocyclic group Chemical group 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 239000001301 oxygen Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000003367 polycyclic group Chemical group 0.000 claims 10
- 125000006413 ring segment Chemical group 0.000 claims 10
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- ZZLCFHIKESPLTH-UHFFFAOYSA-N p-methylbiphenyl Natural products C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 6
- 239000003513 alkali Substances 0.000 claims 5
- 235000010290 biphenyl Nutrition 0.000 claims 5
- 239000004305 biphenyl Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 230000011987 methylation Effects 0.000 claims 5
- 238000007069 methylation reaction Methods 0.000 claims 5
- ISDBWOPVZKNQDW-UHFFFAOYSA-N 4-phenylbenzaldehyde Chemical group C1=CC(C=O)=CC=C1C1=CC=CC=C1 ISDBWOPVZKNQDW-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000002524 organometallic group Chemical group 0.000 claims 3
- 238000007142 ring opening reaction Methods 0.000 claims 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims 1
- 238000007239 Wittig reaction Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 238000006880 cross-coupling reaction Methods 0.000 claims 1
- 238000006114 decarboxylation reaction Methods 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims 1
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 230000001035 methylating effect Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 238000007127 saponification reaction Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/18—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
- C07C227/20—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/32—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Claims (78)
1. Spoj, naznačen time, da ima sljedeću formulu (1), njegov tautomer, ili njegova sol:
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil-C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći: C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril- C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil; C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6-alkoksikarbonil; C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil; sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2-.
2. Spoj prema zahtjevu 1, naznačen time, da ima konfiguraciju u skladu sa sljedećom formulom (1-a):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina kako je definirana u zahtjevu 1.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da ima R1 je vodik.
4. Spoj prema zahtjevu 1 ili 2, naznačen time, da R1 je dušikova zaštitna skupina odabrana od sljedećih: pivaloil, pirolidinilmetil, t-butoksikarbonil, benzil, trietilsilil, acetil, benziloksikarbonil (Cbz) i trimetilsilietoksimetil (SEM).
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da spoj je enol-tautomer prema sljedećoj formuli (I'):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina kako je definirana u zahtjevu 1 i R1' je vodik.
6. Spoj, naznačen time, da ima sljedeću formulu (I1), ili njegova sol:
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil-C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći: C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril- C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil; C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C7-alkoksikarbonil; C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil; sukcinidimil-skupina; i SiR'R"R", gdje su R, R" i R" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2, a R1' je vodikova ili kisikova zaštitna skupina formule SiR7R8R9, gdje su R7, R8 i R9 međusobno neovisno C1-C7-alkil ili C6-C10-aril.
7. Spoj prema zahtjevu 6, naznačen time, da ima strukturu prikazanu u sljedećoj formuli (1"):
[image]
u kojoj su R7, R8 i R9 međusobno neovisno C6-C10-aril ili C1-C7-alkil, poželjno metil ili etil.
8. Postupak za proizvodnju spoja prema sljedećoj formuli (2) ili njegove soli.
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća metilaciju spoja prema sljedećoj formuli (1) ili njegove soli:
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina, poželjno obuhvaća metilaciju spoja prema sljedećoj formuli (1-a), ili njegove soli:
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina.
9. Postupak prema zahtjevu 8, naznačen time, da obuhvaća obradu spoja formule (1) ili njegove soli, s lužinom i metilacijskim reagensom, poželjno obuhvaća obradu spoja formule (1-a) ili njegove soli.
10. Postupak prema zahtjevu 8, naznačen time, da obuhvaća sljedeće:
a) obrada spoja formule (1) ili njegove soli, prvo s lužinom i zatim sa spojem formule YCO2R, pri čemu Y je halogen ili -OR' i gdje su R i R' neovisno odabrani od alkila, arila i arilalkila, kako bi se dobio spoj sljedeće formule (20) ili njegova sol:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, R11 je vodik i R10 je OR, dok R je alkil, aril ili arilakil;
b) reakcija dobivenog spoja formule (20) s lužinom i metilacijskim reagensom, kako bi se dobio spoj formule (20) ili njegova sol, pri čemu R1 je vodikova ili dušikova zaštitna skupina, R11 je metil i R10 je OR, dok R je alkil, aril ili arilalkil:
c) po izboru, obrada spoja formule (20) gdje R1 je vodikova ili dušikova zaštitna skupina, R11 je metil i R10 je OR, dok R je alkil, aril ili arilalkil, sa saponifikacijskim reagensom, kako bi se dobio spoj formule (20) ili njegova sol, gdje R1 je vodikova ili dušikova zaštitna skupina, R11 je metil i R10 je OH;
d) obrada spoja dobivenog u koraku (b) ili (c) pod dekarboksilacijskim uvjetima za dobivanje spoja formule (2).
11. Postupak prema zahtjevu 10, naznačen time, daje konfiguracija spoja formule (20) u skladu sa sljedećom formulom (20-a):
[image]
12. Postupak prema bilo kojem od zahtjeva 8 do 10, naznačen time, da se proizvodi spoj ili njegova sol, koji/koja ima konfiguraciju u skladu sa sljedećom formulom (2-a):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina.
13. Postupak prema zahtjevu 8, naznačen time, da se kao početni materijal upotrebljava spoj u skladu s formulom (1-a) ili njegova sol, i proizvodi se spoj u skladu sa formulom (2-a) ili njegova sol, u dijastereomernom omjeru sljedećih dijastereomera (2-a) prema (2-b):
[image]
kao većem od 60 : 40, poželjno većem od 70 : 30.
14. Postupak prema zahtjevu 9, naznačen time, da spoj prema formuli (1) ili njegova sol, ima konfiguraciju u skladu s formulom (1-a) i pri čemu se proizvodi spoj prema formuli (2), u omjeru sljedećih dijastereomera (2-a) prema (2-b):
[image]
od najmanje 80 : 20, poželjno najmanje 91:9.
15. Postupak prema zahtjevu 10 ili 11, naznačen time, da spoj prema formuli (1) ili njegova sol, ima konfiguraciju u skladu s formulom (1-a) i pri čemu se proizvodi spoj prema formuli (2) u omjeru sljedećih dijastereomera (2-a) prema (2-b):
[image]
od najmanje 55 : 45.
16. Postupak prema zahtjevu 10 ili 11, naznačen time, da spoj prema formuli (1) ili njegova sol, ima konfiguraciju u skladu s formulom (1-a) i pri čemu se proizvodi spoj prema formuli (2) u omjeru sljedećih dijastereomera (2-a) prema (2-b):
[image]
od najmanje 29 : 79.
17. Postupak prema bilo kojem od zahtjeva 8 do 16, naznačen time, da dobiveni spoj sljedeće formule (2) ili njegova sol:
[image]
reagira sa sredstvom za otvaranje prstena, kako bi se dobio spoj u skladu sa sljedećom formulom (3) ili njegova sol:
[image]
pri čemu su R1 i R2 u gornjim formulama, međusobno neovisno vodikova ili dušikova zaštitna skupina i R3 je vodik ili alkil.
18. Postupak prema zahtjevu 17, naznačen time, da se dobiva spoj koji ima konfiguraciju u skladu sa sljedećom formulom (3-a) ili njegova sol:
[image]
u kojoj su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina i R3 je vodik ili alkil.
19. Postupak prema zahtjevu 17 ili 18, naznačen time, da su R1 i R2 vodik i R3 je etil-skupina.
20. Postupak prema bilo kojem od zahtjeva 17 do 19, naznačen time, da se proizvodi spoj prema formuli (3) u omjeru sljedećih dijastereomera (3-a) prema (3-b):
[image]
[image]
od najmanje 60 : 40, poželjno najmanje 70 : 30, još poželjnije najmanje 80 : 20, još bolje od najmanje 90 : 10, te najbolje od najmanje 99 : 1.
21. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (18) ili njegove soli:
[image]
naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (1-a) ili njegove soli:
[image]
b) metilacija spoja prema formuli (1-a) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (2-a) ili njegova sol:
[image]
c) reakcija spoja prema formuli (2-a) ili njegove soli, sa sredstvom za otvaranje prstena, kako bi se dobio spoj u skladu sa sljedećom formulom (3-a) ili njegova sol:
[image]
d) reakcija spoja prema formuli (3-a) ili njegove soli, kako bi se dobio spoj u skladu s formulom (18) ili njegova sol;
pri čemu su R1 i R2 u gornjim formulama, međusobno neovisno vodikova ili dušikova zaštitna skupina i R3 je vodik ili alkil.
22. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (4) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina i R4 je CO-aktivacijska skupina;
b) reakcija spoja prema formuli (4) ili njegove soli, s bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (5) ili njegova sol:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina; i
c) redukcija spoja prema formuli (5) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
23. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća redukciju spoja u skladu sa sljedećom formulom (5) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj formule (1) ili njegova sol.
24. Postupak prema zahtjevu 23, naznačen time, da redukcija obuhvaća obradu s vodikom i katalizatorom.
25. Postupak prema zahtjevu 24, naznačen time, da katalizator je Pd/C.
26. Postupak prema zahtjevu 25, naznačen time, da katalizator Pd/C je odabran iz skupine koju čine: 10% Pd/C tipa K-0218, 10% tipa PD CP 4505 D/R, 5% Pd/C tipa 39, 10% Pd/C tipa 39, 10% Pd/C tipa 39 (7200), 20% Pd/C tipa 91, 10% Pd/C tipa 338, 10% Pd/C tipa 394, 10% Pd/C tipa 394 (6065), 10% Pd/C tipa 394 (6249), 10% Pd/C tipa 395, 10% Pd/C tipa 395 (6002), 10% Pd/C tipa mod (72595), 15% Pd/C tipa A101023 i 15% Pd/C tipa A502085.
27. Postupak prema zahtjevu 22, naznačen time, da CO-aktivacijska skupina je odabrana iz skupine koju čine: dimetilamino, morfolinil, imidazolil, metilmetoksiamino, -O-metil, -O-etil, klor, brom, pivaloil i acetil.
28. Postupak prema zahtjevu 27, naznačen time, da R4 u formuli (4) je morfolinil i bifenilni spoj koji se koristi u koraku b) je bifenilmagnezij-halid.
29. Postupak prema zahtjevu 27, naznačen time, da R4 u formuli (4) je klorid i bifenilni spoj koji se koristi u koraku b) je bifenil.
30. Postupak prema bilo kojem od zahtjeva 22 do 29, naznačen time, da je konfiguracija spojeva s formulama (4), (5) i (1) ili njihovih soli, u skladu sa sljedećim formulama (4-a), (5-a) i (1-a):
[image]
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina i R4 je CO-aktivacijska skupina.
31. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (7) ili njegove soli:
[image]
gdje su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina,
b) reakcija spoja prema formuli (7) ili njegove soli, u Wittigovoj reakciji, kako bi se dobio spoj u skladu sa sljedećom formulom (8) ili njegova sol:
[image]
gdje su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina i R5 je vodik ili alkil,
c) redukcija spoja prema formuli (8) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (9) ili njegova sol:
[image]
gdje su R1 i R2 međusobno neovisno vodikova ili dušikova zaštitna skupina i R5 je vodik ili alkil,
d) po izboru, odstranjivanje dušikovih zaštitnih skupina, čime se dobiva spoj u skladu sa sljedećom formulom (10) ili njegova sol:
[image]
gdje R5 je vodik ili alkil, i
e) reakcija spoja prema formuli (10) ili njegove soli, pri čemu R5 je vodik ili alkil, pod uvjetima zatvaranja prstena, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
32. Postupak prema zahtjevu 31, naznačen time, daje konfiguracija spojeva ili njihovih soli, u skladu sa sljedećim formulama (1-a) i od (7-a) do (10-a):
[image]
[image]
[image]
gdje su R1 i R2 u gornjim formulama, međusobno neovisno vodikova ili dušikova zašttina skupina i R5 je vodik ili alkil.
33. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća rekciju spoja u skladu sa sljedećom formulom (11) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina i R6 je izlazna skupina, s aktiviranim bifenilnim spojem.
34. Postupak prema zahtjevu 33, naznačen time, da aktivirani bifenilni spoj je bifenilmagnezij-halid.
35. Postupak prema zahtjevu 33 ili 34, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi pod reakcijskim uvjetima Fe-kataliziranog ili Mn-kataliziranog križnog spajanja.
36. Postupak prema zahtjevu 35, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi uz pomoć uporabe FeCl3, Fe(acac)3 ili MnCk
37. Postupak prema zahtjevu 33 ili 34, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi u prisutnosti metalne soli kao aditiva.
38. Postupak prema bilo kojem od zahtjeva 33 do 37, naznačen time, da se upotrebljava spoj formule (11) ili njegova sol, koji ima konfirguraciju u skladu sa sljedećom formulom (11-a):
[image]
pri čemu R1 je vodikova ili dušikova zaštitna skupina i R6 je izlazna skupina.
39. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (12) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina,
b) reakcija spoja prema formuli (12) ili njegove soli, s aktiviranim (naime metaliranim) bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (13) ili njegova sol:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, i
c) redukcija spoja prema formuli (13) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
40. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (13) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina,
naznačen time, da navedeni postupak obuhvaća reakciju spoja u skladu sa sljedećom formulom (12) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina s aktiviranim bifenilnim spojem, kako bi se dobio spoj formule (13).
41. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačena time, da navedeni postupak obuhvaća redukciju spoja u skladu sa sljedećom formulom (13) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
42. Postupak prema bilo kojem od zahtjeva 39 do 41, naznačen time, da spojevi s formulama (12) i (13) ili njihove soli, imaju konfiguraciju u skladu sa sljedećim formulama (12-a) i (13-a):
[image]
[image]
pri čemu u gornjim formulama R1 je vodikova ili dušikova zaštitna skupina.
43. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (14) ili njegove soli:
[image]
b) reakcija spoja prema formuli (14) ili njegove soli, s 4-formil-bifenilom, kako bi se dobio spoj u skladu sa sljedećom formulom (15) ili njegova sol:
[image]
c) hidrogenizacija spoja formule (15) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (16) ili njegova sol:
[image]
i
d) redukcija spoja prema formuli (16) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol;
pri čemu u formulama od (14) do (16), R1 je vodikova ili dušikova zaštitna skupina.
44. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (16) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća hidrogenizaciju spoja u skladu sa sljedećom formulom (15) ili njegove soli:
[image]
pri čemu R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (16).
45. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća redukciju spoja u skladu sa sljedećom formulom (16) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
46. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća hidrogenizaciju spoja u skladu sa sljedećom formulom (15) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
47. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća hidrogenizaciju spoja u skladu sa sljedećom formulom (21) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
48. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (14) ili njegove soli:
[image]
b) reakcija spoja prema formuli (14) ili njegove soli, s 4-formil-bifenilom, kako bi se dobio spoj u skladu sa sljedećom formulom (15) ili njegova sol:
[image]
c) redukcija spoja formule (15) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (21) ili njegova sol:
[image]
i
d) hidrogenizacija spoja prema formuli (21) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol, pri čemu u formulama (14), (15) i (21), R1 je vodikova ili dušikova zaštitna skupina.
49. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (14) ili njegove soli:
[image]
b) reakcija spoja prema formuli (14) ili njegove soli, s 4-formil-bifenilom, kako bi se dobio spoj u skladu sa sljedećom formulom (15) ili njegova sol:
[image]
c) hidrogenizacija spoja formule (15) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol;
pri čemu u formulama (14) i (15), R1 je vodikova ili dušikova zaštitna skupina.
50. Postupak prema bilo kojem od zahtjeva 43, 44, 46, 47 i 48, naznačen time, da se hidrogenizacija izvodi pod reakcijskim uvjetima enantioselektivne hidrogenizacije.
51. Postupak prema bilo kojem od zahtjeva 43 do 50, naznačen time, da spojevi s formulama (1) i (16) ili njihove soli, imaju konfiguraciju u skladu sa sljedećim formulama (1-a) i (16-a):
[image]
pri čemu u gornjim formulama, Rl je vodikova ili dušikova zaštitna skupina.
52. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (15) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća reakciju spoja u skladu sa sljedećom formulom (14) ili njegove soli:
[image]
s 4-formil-bifenilom, kako bi se dobio spoj formule (15).
53. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (21) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća redukciju spoja u skladu sa sljedećom formulom (15) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj formule (21).
54. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (16) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća reakciju spoja u skladu sa sljedećom formulom (14) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, sa spojem 4-metil-bifenil formule 4-bifenil-CH2-X, gdje X je izlazna skupina, kako bi se dobio spoj u skladu s formulom (16) ili njegova sol, u prisutnosti lužine, poželjno u prisutnosti lužine i kiralne faze prijelaznog katalizatora.
55. Postupak prema zahtjevu 54, naznačen time, da je konfiguracija spoja formule (16) ili njegove soli, u skladu sa sljedećom formulom (16-a):
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina.
56. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (15) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća reakciju spoja u skladu sa sljedećom formulom (17) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, s organometalnim reagensom izvedenim iz 4-metil-bifenila, kako bi se dobio spoj u skladu s formulom (15) ili njegova sol.
57. Uporaba spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačena time, da služi kao intermedijer ili početni materijal u sintezi N-(3-karboksil-1-oksopropil)-(4S)-(p-fenilfenilmetil)-4-amino-(2R)-metil-butanska kiselina-etilester
predlijeka kao NEP-inhibitora, ili njegove soli.
58. Uporaba prema zahtjevu 57, naznačena time, da spoj ili njegova sol ima konfiguraciju u skladu sa sljedećom formulom (1-a):
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina.
59. Uporaba prema zahtjevu 58, naznačena time, da se sinteza provodi u skladu s postupkom opisanom u zahtjevu 21.
60. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (2):
[image]
u kojoj Rl je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći:
C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril-C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil;
C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6-alkoksikarbonil;
C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil;
sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2, koji poželjno ima konfiguraciju u skladu sa sljedećom formulom (2-a):
[image]
61. Spoj prema zahtjevu 60, naznačen time, da u formuli (2-a), R1 je vodikova ili dušikova zaštitna skupina odabrana od pivaloila i t-butiloksikarbonila (BOC).
62. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (2'):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s
tri-C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći: C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril- C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil; C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6- alkoksikarbonil; C6-C10-aril-C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil; sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2, i R1' je vodikova ili kisikova zaštitna skupina formule SiR7R8R9, pri čemu su R7, R8 i R9 međusobno neovisno C1-C7-alkil ili C6-C10-aril, koji poželjno ima konfiguraciju u skladu sa sljedećom formulom (2'-a):
[image]
63. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (13):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom,
dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći:
C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril- C1-C2-alkoksikarbonil; C6-C10-alkeniloksikarbonil;
C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6-alkoksikarbonil;
C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil;
sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički. nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2, koji poželjno ima konfiguraciju u skladu sa sljedećom formulom (13-a):
[image]
64. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (15):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći:
C1-C7-alkil, hidroksil, C1-C7 -alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril-C1-C2-alkoksikarbonil; C6-C10-alkeniloksikarbonil;
C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6-alkoksikarbonil;
C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil;
sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2.
65. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (16):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći:
C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril-C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil; C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6- alkoksi karbonil; C6-C10-aril-C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil; sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2, koji poželjno ima konfiguraciju u skladu sa sljedećom formulom (16-a):
[image]
66. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (20):
[image]
koji poželjno ima konfiguraciju u skladu sa sljedećom formulom (20-a):
[image]
pri čemu u gornjoj formuli, R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći: C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril- C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil; C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6-alkoksikarbonil; C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil; sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2, R10 je skupina -OR gdje R je C1-C7-alkil, C6-C10-aril ili C6-C10-aril- C1-C7-alkil i R11 je vodik ili metil.
67. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (21):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom, dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći: C1-C7-alkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril-C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil; C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6- alkoksi karbonil; C6-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil; sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2.
68. Spoj ili njegova sol, naznačen/a time, da je u skladu sa sljedećom formulom (22):
[image]
u kojoj R1 je vodikova ili dušikova zaštitna skupina odabrana iz skupine koju čine: C1-C6-alkil, koja je mono- ili di- ili trisupstituirana s tri- C1-C7-alkilsilil- C1-C7-alkoksi, C6-C10-arilom, ili heterocikličkom skupinom,
dok je arilni prsten ili heterociklička skupina nesupstituiran/a ili supstituiran/a s jednim, dva ili tri ostatka odabrana iz skupine koju čine sljedeći:
C1-C7-valkil, hidroksil, C1-C7-alkoksi, C2-C8-alkanoil-oksi, halogen, nitro, cijano, i CF3;
C6-C10-aril-C1-C2-alkoksikarbonil; C1-C10-alkeniloksikarbonil;
C1-C6-alkilkarbonil; C6-C10-arilkarbonil; C1-C6-alkoksikarbonil;
C5-C10-aril- C1-C6-alkoksikarbonil; alil; cinamil; sulfonil; sulfenil;
sukcinidimil-skupina; i SiR'R"R", gdje su R', R" i R'" međusobno neovisno C1-C7-alkil, C6-C10-aril ili fenil- C1-C4-alkil; pri čemu navedeni heterociklil je monociklički ili policiklički, nezasićeni, djelomično zasićeni, zasićeni ili aromatski sustav prstena koji ima od 5 do 14 atoma prstena i s jednim ili više heteroatoma neovisno odabranima od dušika, kisika, sumpora, S(=O)- ili S-(=O)2.
69. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (6), ili njegove soli:
[image]
b) reakcija spoja prema formuli (6) ili njegove soli, s organometalnim reagensom izvedenim iz 4-metil-bifenila, kako bi se dobio spoj u skladu sa sljedećom formulom (22) ili njegova sol:
[image]
c) dehidratacija spoja formule (22) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (21) ili njegova sol:
[image]
d) hidrogenizacija spoja prema formuli (21) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol, pri čemu u formulama (6), (22) i (21), Rl je vodikova ili dušikova zaštitna skupina.
70. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (22) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća reakciju spoja u skladu sa sljedećom formulom (6) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, s organometalnim reagensom izvedenim iz 4-metil-bifenila, kako bi se dobio spoj u skladu s formulom (22) ili njegova sol.
71. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (21) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća dehidrataciju spoja u skladu sa sljedećom formulom (22) ili njegove soli:
[image]
gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (21) ili njegova sol.
72. Postupak prema zahtjevu 69, naznačen time, da se hidrogenizacija izvodi pod reakcijskim uvjetima enantioselektivne hidrogenizacije.
73. Postupak prema zahtjevu 69 ili 72, naznačen time, da spoj formule (1) ili njegova sol, ima konfiguraciju u skladu sa sljedećom formulom (1-a):
[image]
pri čemu u gornjoj formuli, R1 je vodikova ili dušikova zaštitna skupina.
74. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (18) ili njegove soli:
[image]
naznačen time, da obuhvaća sljedeće korake:
a) dobava spoja u skladu sa sljedećom formulom (1) ili njegove soli:
[image]
b) metilacija spoja prema formuli (1) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (2) ili njegova sol:
[image]
c) reakcija spoja prema formuli (2) ili njegove soli, sa sredstvom za otvaranje prstena, kako bi se dobio spoj u skladu sa sljedećom formulom (3) ili njegova sol:
[image]
d) reakcija spoja prema formuli (3) ili njegove soli, kako bi se dobio spoj u skladu s formulom (18) ili njegova sol, pri čemu u gornjim formulama, R1 i R2 su međusobno neovisno vodikova ili dušikova zaštitna skupina i R3 je vodik ili alkil.
75. Postupak prema zahtjevu 74, naznačen time, da se spoj formule (1) ili njegova sol, proizvodi u skladu s postupkom koji je definiran u bilo kojem do zahtjeva 22, 23, 31, 33, 39, 41, 43, 45, 46, 47, 48, 49 ili 69.
76. Postupak prema zahtjevu 74, naznačen time, da se
- spoj formule (1) ili njegova sol, proizvodi u skladu s postupkom koji je definiran u bilo kojem do zahtjeva 22, 23, 31, 33, 39, 41, 43, 45, 46, 47, 48, 49 ili 69, i
- spoj formule (2) ili njegova sol, proizvodi u skladu s bilo kojem od zahtjeva 8 do 16.
77. Postupak prema bilo kojem od zahtjeva 74 do 76, naznačen time, da je konfiguracija spojeva s formulama (1), (2) i (3), ili njihovih soli, u skladu sa sljedećim formulama (1-a), (2-a) i (3-a):
[image]
[image]
78. Spoj prema zahtjevu 60, naznačen time, daje u kristalnom obliku.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07100451 | 2007-01-12 | ||
EP08706986.0A EP2121578B1 (en) | 2007-01-12 | 2008-01-10 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
PCT/EP2008/000142 WO2008083967A2 (en) | 2007-01-12 | 2008-01-10 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161484T1 true HRP20161484T1 (hr) | 2016-12-16 |
Family
ID=38124137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161484TT HRP20161484T1 (hr) | 2007-01-12 | 2016-11-09 | Postupak za proizvodnju 5-bifenil-4-amino-2-metil-pentanske kiseline |
Country Status (36)
Country | Link |
---|---|
US (4) | US8115016B2 (hr) |
EP (1) | EP2121578B1 (hr) |
JP (1) | JP5715339B2 (hr) |
KR (2) | KR101580067B1 (hr) |
CN (1) | CN101631765B (hr) |
AR (1) | AR064842A1 (hr) |
AU (2) | AU2008204546B2 (hr) |
BR (1) | BRPI0806700A8 (hr) |
CA (1) | CA2674291C (hr) |
CL (1) | CL2008000077A1 (hr) |
CO (1) | CO6251311A2 (hr) |
CY (1) | CY1118225T1 (hr) |
DK (1) | DK2121578T3 (hr) |
EC (1) | ECSP099508A (hr) |
ES (1) | ES2602566T3 (hr) |
GT (1) | GT200900195A (hr) |
HK (1) | HK1139122A1 (hr) |
HR (1) | HRP20161484T1 (hr) |
HU (1) | HUE030695T2 (hr) |
IL (1) | IL199492A (hr) |
JO (1) | JO3142B1 (hr) |
LT (1) | LT2121578T (hr) |
MA (1) | MA31284B1 (hr) |
MX (1) | MX2009007474A (hr) |
MY (2) | MY153432A (hr) |
NZ (1) | NZ577910A (hr) |
PE (2) | PE20081563A1 (hr) |
PL (1) | PL2121578T3 (hr) |
PT (1) | PT2121578T (hr) |
RU (1) | RU2530900C2 (hr) |
SG (1) | SG185318A1 (hr) |
SI (1) | SI2121578T1 (hr) |
TN (1) | TN2009000296A1 (hr) |
TW (1) | TWI413638B (hr) |
WO (1) | WO2008083967A2 (hr) |
ZA (1) | ZA200904311B (hr) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2121578T (lt) * | 2007-01-12 | 2016-11-25 | Novartis Ag | 5-bifenil-4-amino-2-metilpentano rūgšties gavimo būdas |
AU2012202949B2 (en) * | 2008-01-17 | 2015-01-22 | Novartis Ag | Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives |
PE20091364A1 (es) * | 2008-01-17 | 2009-10-13 | Novartis Ag | Proceso para la preparacion de inhibidores de nep |
CN103896796B (zh) | 2009-05-28 | 2016-04-27 | 诺华股份有限公司 | 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物 |
JP5466759B2 (ja) | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
PT2526088E (pt) * | 2010-01-22 | 2015-11-03 | Novartis Ag | Intermediários dos inibidores da endopeptidase neutra e método de preparação dos mesmos |
EP2609071B1 (en) | 2010-08-23 | 2016-09-21 | Novartis AG | New process for the preparation of intermediates useful for the manufacture of nep inhibitors |
KR101476937B1 (ko) | 2010-08-23 | 2014-12-24 | 노파르티스 아게 | Nep 억제제의 제조를 위한 중간체의 제조 방법 |
US8877815B2 (en) * | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8586536B2 (en) | 2010-12-15 | 2013-11-19 | Theravance, Inc. | Neprilysin inhibitors |
AU2011343903B2 (en) | 2010-12-15 | 2016-06-30 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
RU2604522C2 (ru) | 2011-02-17 | 2016-12-10 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи,ЭлЭлСи | Замещенные аминомасляные производные в качестве ингибиторов неприлизина |
US8449890B2 (en) | 2011-02-17 | 2013-05-28 | Theravance, Inc. | Neprilysin inhibitors |
EP2714660B1 (en) | 2011-05-31 | 2018-09-26 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
ES2642883T3 (es) | 2011-05-31 | 2017-11-20 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
TWI562986B (en) * | 2012-02-15 | 2016-12-21 | Theravance Biopharma R&D Ip Llc | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds |
ES2609810T3 (es) | 2012-05-31 | 2017-04-24 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina donadores de óxido nítrico |
MX356260B (es) | 2012-06-08 | 2018-05-21 | Theravance Biopharma R&D Ip Llc | Inhibidores de la neprilisina. |
CN104470521B (zh) | 2012-06-08 | 2017-04-12 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
LT2882716T (lt) | 2012-08-08 | 2017-02-10 | Theravance Biopharma R&D Ip, Llc | Neprilizino inhibitoriai |
NZ710574A (en) | 2013-02-14 | 2017-11-24 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
AU2014216417B2 (en) | 2013-02-14 | 2016-05-12 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
SI2964616T1 (sl) | 2013-03-05 | 2017-08-31 | Theravance Biopharma R&D Ip, Llc | Zaviralci neprilizina |
CN104230865B (zh) * | 2013-06-13 | 2018-01-09 | 上海翰森生物医药科技有限公司 | 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途 |
AU2015211041B2 (en) | 2014-01-30 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
KR20160113291A (ko) | 2014-01-30 | 2016-09-28 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프리리신 저해제 |
PL3218351T3 (pl) | 2014-11-14 | 2019-12-31 | Zentiva K.S. | Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377 |
CN107074744B (zh) * | 2014-12-03 | 2019-06-18 | 上海翰森生物医药科技有限公司 | Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用 |
CN104557600B (zh) * | 2015-01-26 | 2016-05-04 | 苏州明锐医药科技有限公司 | 沙库比曲的制备方法 |
AU2016219362B2 (en) | 2015-02-11 | 2019-11-14 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor |
TW201632493A (zh) | 2015-02-13 | 2016-09-16 | 諾華公司 | 新穎方法 |
EP3259255B1 (en) | 2015-02-19 | 2020-10-21 | Theravance Biopharma R&D IP, LLC | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
WO2016135751A1 (en) | 2015-02-25 | 2016-09-01 | Mylan Laboratories Limited | Novel process for the preparation of sacubitril and its intermediates |
CN106187808A (zh) * | 2015-05-08 | 2016-12-07 | 苏州鹏旭医药科技有限公司 | Ahu-377的制备方法、ahu-377中间体及ahu-377中间体的制备方法 |
CN104829514B (zh) * | 2015-05-12 | 2017-10-03 | 江苏福瑞生物医药有限公司 | 一种药物中间体的合成方法 |
CN104926707B (zh) * | 2015-05-12 | 2017-10-27 | 江苏福瑞生物医药有限公司 | 一种药物中间体的合成方法 |
CN104860894B (zh) * | 2015-06-10 | 2017-05-17 | 北京博全健医药科技有限公司 | 一种抗心衰药lcz696的制备方法 |
WO2016203500A2 (en) * | 2015-06-19 | 2016-12-22 | Actavis Group Ptc Ehf. | Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril |
JP6748123B2 (ja) * | 2015-07-02 | 2020-08-26 | ノバルティス アーゲー | サクビトリルカルシウム塩 |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
CN105061263B (zh) * | 2015-08-11 | 2017-03-15 | 苏州楚凯药业有限公司 | 一种nep抑制剂中间体的制备方法 |
CN105168205A (zh) * | 2015-08-18 | 2015-12-23 | 泰力特医药(湖北)有限公司 | 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法 |
WO2017033128A1 (en) | 2015-08-25 | 2017-03-02 | Novartis Ag | Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors |
CN105130869B (zh) * | 2015-09-07 | 2017-12-26 | 曾伟 | 一种Entresto中间体(S)‑5‑(联苯‑4‑羰基)吡咯烷‑2‑酮的合成方法 |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
CN105348209B (zh) | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
CN105523964B (zh) * | 2015-12-09 | 2017-05-24 | 苏州楚凯药业有限公司 | 一种抗心衰药物中间体的制备方法 |
JP7001597B2 (ja) * | 2015-12-10 | 2022-01-19 | ノバルティス アーゲー | 新規なプロセスおよび中間体 |
WO2017097275A1 (en) | 2015-12-11 | 2017-06-15 | Zentiva, K.S. | Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method |
CN106977415B (zh) * | 2016-01-15 | 2021-03-26 | 广东东阳光药业有限公司 | 一种沙库必曲的中间体及其制备方法 |
CN105566194A (zh) * | 2016-02-01 | 2016-05-11 | 张伯引 | 一种Sacubitril中间体的制备方法 |
WO2017148357A1 (zh) * | 2016-02-29 | 2017-09-08 | 广东东阳光药业有限公司 | 一种沙库必曲的中间体及其制备方法 |
SG11201807591VA (en) | 2016-03-08 | 2018-10-30 | Theravance Biopharma R&D Ip Llc | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
WO2017191620A1 (en) * | 2016-05-06 | 2017-11-09 | Sun Pharmaceutical Industries Limited | A crystalline form of a salt of sacubitril and a process of its preparation |
CN105924355B (zh) * | 2016-05-11 | 2018-08-17 | 浙江宏元药业有限公司 | 沙库比曲中间体及沙库比曲中间体和沙库比曲的制备方法 |
WO2018007919A1 (en) | 2016-07-05 | 2018-01-11 | Novartis Ag | New process for early sacubitril intermediates |
CN107602399B (zh) * | 2016-07-11 | 2020-09-25 | 江西东邦药业有限公司 | 一种脑啡肽酶抑制剂中间体的制备方法 |
JP6945619B2 (ja) * | 2016-08-17 | 2021-10-06 | ノバルティス アーゲー | Nep阻害剤合成のための新規な方法および中間体 |
CN106496055A (zh) * | 2016-10-09 | 2017-03-15 | 杭州科巢生物科技有限公司 | 一种抗心衰新药的关键组分沙库比曲的新合成方法 |
EP3522886A4 (en) * | 2016-10-10 | 2020-02-19 | Laurus Labs Limited | STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF |
WO2018116203A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | New process for early sacubitril intermediates |
CN107311909A (zh) * | 2017-06-22 | 2017-11-03 | 东南大学 | 一种lcz696杂质对照品的制备方法 |
CN109206419B (zh) * | 2017-06-29 | 2023-07-14 | 上海迪赛诺化学制药有限公司 | 沙库比曲中间体及其制备方法和应用 |
WO2019110371A1 (en) * | 2017-12-05 | 2019-06-13 | Basf Se | Organic sulfonic acid salts of amino acid esters and process for their preparation |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
CN110407733A (zh) * | 2018-04-26 | 2019-11-05 | 鲁南制药集团股份有限公司 | 一种沙库巴曲杂质化合物 |
CN110551151A (zh) * | 2018-05-30 | 2019-12-10 | 微宏动力系统(湖州)有限公司 | 一种磷酸酯或亚磷酸酯的制备方法、电解液及二次电池 |
CN108727213B (zh) * | 2018-06-29 | 2021-06-08 | 中国科学院上海有机化学研究所 | 一种沙库必曲的制备方法 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化(上海)新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
CN109400504A (zh) * | 2018-12-11 | 2019-03-01 | 重庆三圣实业股份有限公司 | Lcz696中间体非对映异构体的分离纯化方法 |
CN113286780A (zh) * | 2019-01-08 | 2021-08-20 | 巴斯夫欧洲公司 | 制备氨基酸酯的有机硫酸盐的方法 |
CN109912486B (zh) * | 2019-04-25 | 2022-09-27 | 东北制药集团股份有限公司 | 一种联苯甲基内酰胺化合物的制备方法 |
CN110878039A (zh) * | 2019-12-18 | 2020-03-13 | 株洲千金药业股份有限公司 | 一种沙库巴曲缬沙坦钠杂质的制备方法 |
JP7064527B2 (ja) * | 2020-05-01 | 2022-05-10 | ノバルティス アーゲー | サクビトリルカルシウム塩 |
BR112023000293A2 (pt) | 2020-07-09 | 2023-03-21 | Advansix Resins & Chemicals Llc | Tensoativos de aminoácidos ramificados |
EP4178537A1 (en) | 2020-07-13 | 2023-05-17 | AdvanSix Resins & Chemicals LLC | Branched amino acid surfactants for use in healthcare products |
BR112023000467A2 (pt) | 2020-07-13 | 2023-01-31 | Advansix Resins & Chemicals Llc | Tensoativos de aminoácidos ramificados para tintas, tintas para pintura e adesivos |
CN115677521B (zh) * | 2022-11-16 | 2024-02-02 | 迪嘉药业集团股份有限公司 | 一种高纯度沙库巴曲钙的制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5015793B2 (hr) | 1972-06-07 | 1975-06-07 | ||
DE3164237D1 (en) | 1980-12-23 | 1984-07-19 | Air Ind | Thermo-electrical plants |
FR2597100A1 (fr) | 1986-01-21 | 1987-10-16 | Nippon Shinyaku Co Ltd | Derives du pyroglutamide |
PH24872A (en) | 1986-08-25 | 1990-12-26 | Schering Corp | (5r,6s,8r)-6-(-1-hydroxyethyl)-2-(3r-pyrrolidin-2-one-3-yl)thiopenem-3-carboxylic acid |
JPH07103101B2 (ja) | 1989-07-24 | 1995-11-08 | キッセイ薬品工業株式会社 | ピログルタミン酸誘導体 |
PH30484A (en) | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
US5273990A (en) | 1992-09-03 | 1993-12-28 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives |
US5250522A (en) * | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
DE69324106T2 (de) | 1992-11-17 | 1999-12-09 | Sankyo Co | Krystallines Carbapenemderivat |
ZA938438B (en) * | 1992-11-17 | 1994-06-20 | Sankyo Co | Crystalline carbapenem derivative |
US5550119A (en) | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
KR19990082639A (ko) * | 1996-02-19 | 1999-11-25 | 미즈노 마사루 | 당뇨병 치료제 |
CA2344412A1 (en) * | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Thiol compound, their production and use |
RU2334513C3 (ru) | 2002-01-17 | 2017-10-24 | Новартис Аг | Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep) |
AU2003236180A1 (en) | 2002-03-29 | 2003-10-13 | Senju Pharmaceutical Co., Ltd. | Hydroxymorpholinone derivative and medicinal use thereof |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
DE602005003572T2 (de) | 2004-05-07 | 2008-04-17 | Umicore Ag & Co. Kg | Ferrocenylliganden für homogene, enantioselektive hydrierungskatalysatoren |
GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
MY146830A (en) | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
EP1903027A1 (en) * | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
LT2121578T (lt) * | 2007-01-12 | 2016-11-25 | Novartis Ag | 5-bifenil-4-amino-2-metilpentano rūgšties gavimo būdas |
-
2008
- 2008-01-10 LT LTEP08706986.0T patent/LT2121578T/lt unknown
- 2008-01-10 HU HUE08706986A patent/HUE030695T2/en unknown
- 2008-01-10 TW TW097101036A patent/TWI413638B/zh not_active IP Right Cessation
- 2008-01-10 PT PT87069860T patent/PT2121578T/pt unknown
- 2008-01-10 SI SI200831697A patent/SI2121578T1/sl unknown
- 2008-01-10 ES ES08706986.0T patent/ES2602566T3/es active Active
- 2008-01-10 KR KR1020147014443A patent/KR101580067B1/ko active IP Right Grant
- 2008-01-10 RU RU2009130534/04A patent/RU2530900C2/ru active
- 2008-01-10 SG SG2012077715A patent/SG185318A1/en unknown
- 2008-01-10 EP EP08706986.0A patent/EP2121578B1/en active Active
- 2008-01-10 MY MYPI20092892A patent/MY153432A/en unknown
- 2008-01-10 JP JP2009545143A patent/JP5715339B2/ja active Active
- 2008-01-10 NZ NZ577910A patent/NZ577910A/en not_active IP Right Cessation
- 2008-01-10 US US12/522,767 patent/US8115016B2/en active Active
- 2008-01-10 WO PCT/EP2008/000142 patent/WO2008083967A2/en active Application Filing
- 2008-01-10 AU AU2008204546A patent/AU2008204546B2/en active Active
- 2008-01-10 MX MX2009007474A patent/MX2009007474A/es unknown
- 2008-01-10 PL PL08706986T patent/PL2121578T3/pl unknown
- 2008-01-10 DK DK08706986.0T patent/DK2121578T3/en active
- 2008-01-10 BR BRPI0806700A patent/BRPI0806700A8/pt not_active IP Right Cessation
- 2008-01-10 CN CN200880008018.9A patent/CN101631765B/zh active Active
- 2008-01-10 KR KR1020097016747A patent/KR101560005B1/ko active IP Right Grant
- 2008-01-10 CA CA2674291A patent/CA2674291C/en active Active
- 2008-01-10 AR ARP080100105A patent/AR064842A1/es unknown
- 2008-01-10 MY MYPI20124466 patent/MY151993A/en unknown
- 2008-01-11 PE PE2008000125A patent/PE20081563A1/es not_active Application Discontinuation
- 2008-01-11 CL CL200800077A patent/CL2008000077A1/es unknown
- 2008-01-11 PE PE2012000840A patent/PE20121615A1/es not_active Application Discontinuation
- 2008-01-13 JO JOP/2008/0014A patent/JO3142B1/ar active
-
2009
- 2009-06-19 ZA ZA200904311A patent/ZA200904311B/xx unknown
- 2009-06-22 IL IL199492A patent/IL199492A/en active IP Right Grant
- 2009-07-08 GT GT200900195A patent/GT200900195A/es unknown
- 2009-07-10 TN TNP2009000296A patent/TN2009000296A1/fr unknown
- 2009-07-10 EC EC2009009508A patent/ECSP099508A/es unknown
- 2009-07-13 CO CO09072494A patent/CO6251311A2/es active IP Right Grant
- 2009-08-04 MA MA32142A patent/MA31284B1/fr unknown
-
2010
- 2010-05-17 HK HK10104781.3A patent/HK1139122A1/zh unknown
-
2011
- 2011-12-21 US US13/333,437 patent/US8716495B2/en active Active
-
2012
- 2012-05-29 AU AU2012203155A patent/AU2012203155B2/en active Active
-
2014
- 2014-03-25 US US14/224,700 patent/US8993785B2/en active Active
-
2015
- 2015-02-20 US US14/627,542 patent/US9206116B2/en active Active
-
2016
- 2016-11-09 CY CY20161101157T patent/CY1118225T1/el unknown
- 2016-11-09 HR HRP20161484TT patent/HRP20161484T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161484T1 (hr) | Postupak za proizvodnju 5-bifenil-4-amino-2-metil-pentanske kiseline | |
ES2542237T3 (es) | Procedimiento de producción de un derivado de diamina ópticamente activo | |
ES2728353T3 (es) | Compuesto de (6S,9aS)-N-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1H-pirazino[2,1-c][1,2,4]triazin-1-carboxamida | |
US20120010413A1 (en) | Process for the Preparation of Pyrido [2,1-a] Isoquinoline Derivatives by Catalytic Asymmetric Hydrogenation of an Enamine | |
EA018913B1 (ru) | Способ получения защищенных производных l-аланина | |
ES2679744T3 (es) | Procedimiento para producir derivados de tiazol | |
HUT71701A (en) | Alpha-aminoalkanoicacids and reductionsproduct | |
WO2006065826A2 (en) | Process to chiral beta amino acid derivatives by asymmetric hydrogenation | |
WO2014157612A1 (ja) | (1s,4s,5s)-4-ブロモ-6-オキサビシクロ[3.2.1]オクタン-7-オンの製造方法 | |
AU2011295171A1 (en) | New process for the preparation of intermediates useful for the manufacture NEP inhibitors | |
HRP20160540T1 (hr) | Sol i solvati jednog derivata tetrahidroizokinolina | |
CA2591738A1 (en) | Process for making substituted piperidines | |
JP6340409B2 (ja) | キラルキヌレニン化合物の合成方法 | |
EP3733648B1 (en) | Method for preparing 5r-benzyloxyaminopiperidin-2s-carboxylic acid or derivative thereof | |
CN103732593A (zh) | 喹唑啉-2,4-二酮衍生物 | |
WO2018007919A1 (en) | New process for early sacubitril intermediates | |
CN107001289A (zh) | N‑酰基‑(3‑取代的)‑(8‑取代的)‑5,6‑二氢‑[1,2,4]三唑并[4,3‑a]吡嗪的新手性合成 | |
WO2008088690A2 (en) | A process for preparing diazabicyclo[3.3.1] nonane compounds | |
MX2012009473A (es) | Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas. | |
WO2017033128A1 (en) | Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors | |
EP2733138B1 (en) | Method for producing optically active tetrahydroquinoline | |
KR101998768B1 (ko) | 비천연 아미노산의 제조방법 | |
CN105399755B (zh) | 一种氟氧头孢酸的合成方法 | |
ES2912656T3 (es) | Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico | |
CN114409585A (zh) | 2-氧吡咯烷衍生物、其制备方法及中间体的制备方法 |